Objective To summarize the image diagnosis and treatnent of lumar spinal canal stenosis caused by lumbar posterior marginal intraosseous cartilaginous node(LPMN)and discuss its ralated pathogenic factors.Methods 16 cases of lumbar spinal canal stenosis caused by LPMN undergone susgical treatmeut from 1989 to 1999 were reviewed.Results The typical imaging findings included:(1)a defect in the posterior superior margin of the affected vertebral body,with sclerotic margin;(2)posterior to the defect,a bony fragment was seen protruding into the spinal canal;(3)compression of the dural sac and nerve root.Conclusion Imaging examniation can provide reliable evidence for diagnosis of lumbar spinal canal stenosis caused by lumbar posterior marginal intraosseous cartilagous node and is help planning treatment protocol.

Objective:To adapt to the new review requirements of third level of first-class hospital, passed the hospital informationization evaluation successfully, to promote the continuous development of hospital informatization.Methods: Analysis standard from the section level and hospital level One by one, find out the gap, implement of rectification from the written materials, application of information system and the function point, server and network hardware.Results:The hospital pay high attention to and strongly support as well as the efforts of all staff of our department, through the review of hospital informationization disposable.Conclusion:The hospital informationization construction only carries on, there is no complete, must improve continually, make unremitting efforts to improve hospital management and service level.

Objective To observe the curative effect pemetrexed combined with nadaplatin for advanced NSCLC its impact on the quality of life. Methods 60 patients with advanced NSCLC were randomly divided into control group (30 cases) and observation group (30 cases). The control group was treated with pemetrexed and cisplatin,the observation group was treated with pemetrexed and nadaplatin. The treatment cycle was three weeks, and the efficacy and toxic reaction were evaluated after at least 2 cycles. The response rate (RR) and toxicity were evaluated according to RECIST and RTOG, respectively. The eastern cooperative oncology group-performance status (ECOG-PS) and the European organization for research and treatment of cancer QOL questionnaire (EORTC QLQ-C30) was used to evaluated and quality of life, respectively. And the follow-up was carried on after treatment. Results The scores of general health status, fatigue, nausea and vomiting in the observation group EORTC QLQ-C30 scale were better than those in control group (P<0.05); the occurrence rate of gastrointestinal reaction and hypodynamia was 30.0% and 20.0%, which was lower than those in control group of 86.7% and 43.3%. The overall survival rate (70.0% vs 73.3%) and median PFS (6.0 months vs 6.1 months) were not statistically different between the two groups. Conclusion Pemetrexed combined with nadaplatin is effective and tolerable for advanced NSCLC, and can significantly improve the quality of life of patients, and it is worthy of wide clinical use.

Objective To analyze the clinical features and prognostic factors of gastrointestinal stromal tumors. Methods The clinical features and prognostic factors of51 Gastrointestinal Stromal Tumors patients ,who were treated in people`s hospital of xin-jiang ugyur antonomous region from October 1997 to October 2009, were retrospectively analyzed .Results The 1-year, 3-year, 5-year overall survival rates of 51 cases were 85.4%,76.7%,70.7%respectively, a median of 52 months.The 1-year, 3-year, 5-year overall survival rates of the patients with >4 positive lymph nodes were lower than those of patients with ≤4nodes ( P <0.05 ) , The 1-year, 3-year, 5-year overall survival rates of the patients with positive expression of CD 117 were lower than those of patients with negtive CD117( P <0.05).The 1-year, 3-year, 5-yea r overall survival rates of the patients with recurrence and metastasis were low-er than those of patients without ( P <0.05 ) .Conclusions The prognosis of gastrointestinal stromal tumors is related with the posi-tive expression of CD117, recurrence and metastasis .

Objective:To explore whether metoprolol administration before emergency percutaneous coronary inter‐vention (PCI) can reduce incidence rate of reperfusion arrhythmia (RA) or not .Methods :According to random number table ,a total of 80 patients with acute anterior wall myocardial infarction (age< 75 years ,baseline heart rate >70 beats/min ,no PR interval prolongation ) were randomly and equally divided into routine treatment group (didn't receive metoprolol tartrate tablet before emergency PCI ) and metoprolol group (received metoprolol tartrate tablet 25 mg before emergency PCI ) .Incidence rate of RA after PCI was compared between two groups .Results:In metoprolol group ,a total of 32 cases received PCI and eight cases received percutaneous transluminal coronary angioplasty (PTCA);in routine treatment group ,a total of 35 case received PCI and five cases received PTCA ,suc‐cess rates of both groups were 100% .In metoprolol group , RA occurred in 4 cases ,including one case with ventric‐ular fibrillation (VF);in routine treatment group , RA occurred in 15 cases ,including four cases with VF .Inci‐dence rate of RA after emergency PCI in metoprolol group was significantly lower than that of routine treatment group (10.0% vs .37.5% ,P=0.032) .Conclusion:Metoprolol administration before emergency PCI can reduce in‐cidence rate of reperfusion arrhythmia in patients with acute myocardial infarction .

Nasopharyngeal carcinoma (NPC) is a malignant carcinoma that is closely associated with Epstein Barr virus (EBV) infection. After the comprehensive treatment based on modern intensity-modulated radiation therapy, the oncological outcomes can be further improved. The main target of treatment is to increase the efficacy of patients with high risk and recurrent/metastatic (R/M) NPC. Recently, continuous progress has been made in the application of immunotherapy in the field of cancer treatment. Based on the accumulated knowledge on EBV antigen and immune checkpoint inhibitors, significant progress has been made in use of immunotherapy in treating R/M-NPC. Immunotherapy combined with radiotherapy or chemoradiotherapy will become the hot spot in the clinical management of patients with newly-diagnosed high-risk NPC.